The earnings call summary reveals mixed signals: decreased expenses due to completed campaigns, increased G&A expenses, and a net loss. The Q&A highlights promising drug efficacy and regulatory progress, but lacks clear timelines and specifics, causing uncertainty. The potential for large pharma partnerships is a positive, but the unclear management responses and absence of a market cap prevent a strong sentiment. These factors balance each other, leading to a neutral sentiment rating.